AMGEN INC et al v. MYLAN INC. et al

  1. August 22, 2019

    Mylan Partially Beats Amgen Neulasta Biosimilar Claims

    In light of a recent Federal Circuit decision, Amgen Inc. can no longer allege that Mylan Inc.'s proposed Neulasta biosimilar infringed one of its patents, a Pennsylvania federal court ruled Wednesday, granting a joint request from both parties to nix the claim.

  2. April 09, 2018

    Amgen's Patent Not Used In Neulasta Biosimilar, Mylan Says

    Mylan Inc.'s proposed Neulasta biosimilar doesn't use the salt pairs covered in a patent Amgen Inc. is accusing it of infringing, Mylan told a Pennsylvania federal court Friday, hoping to get the claim killed by relying on an argument that got a similar suit over the patent dismissed last month.

  3. September 25, 2017

    Amgen Hits Mylan With Patent Suit Over Neulasta Biosimilar

    Mylan Inc. infringed two of Amgen Inc.'s patents when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patents expired, the biologic maker told a Pennsylvania federal court Friday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!